Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    February 2017
  1. TANG H, Wang S, Xiao G, Schiller J, et al
    Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
    Ann Oncol. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  2. ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
    MicroRNA Related Genetic Variants in Iron Regulatory Genes, Dietary Iron Intake, MicroRNAs and Lung Cancer Risk.
    Ann Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  3. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  4. HUI R, Garon EB, Goldman JW, Leighl NB, et al
    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    January 2017
  5. TSAO MS, Le Teuff G, Shepherd FA, Landais C, et al
    PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
    Ann Oncol. 2017 Jan 30. pii: mdx003. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. LIANG J, Bi N, Wu S, Chen M, et al
    Etoposide and Cisplatin vs Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Trial.
    Ann Oncol. 2017 Jan 30. pii: mdx009. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  7. WOO CG, Seo S, Kim SW, Jang SJ, et al
    Differential protein stability and clinical responses of EML4-ALKfusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2016 Dec 29. pii: mdw693. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. OSORIO JC, Ni A, Chaft JE, Pollina R, et al
    Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw640. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2016
  9. BELANI CP, Chakraborty B, Modi R, Khamar B, et al
    A Randomized Trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  10. LACOUTURE ME
    reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccar
    Ann Oncol. 2016;27:2138-2139.
    PubMed     Text format    


  11. LEE SH, Lee JK, Ahn MJ, Kim DW, et al
    Vandetanib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring RET Rearrangement: A Phase II Clinical Trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  12. REMON J, Soria JC
    Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Ann Oncol. 2016 Oct 25. doi: 10.1093.
    PubMed     Text format    


  13. KANDA S, Goto K, Shiraishi H, Kubo E, et al
    Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  14. NISHIKAWA S, Tambo Y, Ninomiya H, Oguri T, et al
    A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


    September 2016
  15. DICKHOFF C, Hartemink KJ, Kooij J, van de Ven PM, et al
    Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?
    Ann Oncol. 2016.
    PubMed     Text format    


    August 2016
  16. DE BOER P, Dahele MR, Senan S
    Is radical chemo-radiotherapy appropriate in patients with stage IV non-small-cell lung cancer due to cervical lymph node metastases?
    Ann Oncol. 2016.
    PubMed     Text format    


  17. KINOSHITA T, Muramatsu R, Fujita T, Nagumo H, et al
    Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  18. OLAUSSEN KA, Postel-Vinay S
    Predictors of chemotherapy efficacy in Non-Small Cell Lung Cancer : a challenging landscape.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  19. CECCARELLI G, Schietroma I, Corano Scheri G, d'Ettorre G, et al
    Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with Advanced Non-Small-Cell Lung Cancer enrolled in ARCHER-1042 trial.
    Ann Oncol. 2016.
    PubMed     Text format    


  20. JOERGER M, von Pawel J, Kraff S, Fischer JR, et al
    Open-label, randomised study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  21. MANSFIELD AS, Aubry MC, Moser J, Harrington S, et al
    Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  22. BROWER JV, Amini A, Chen S, Hullett CR, et al
    Improved survival with dose escalated radiotherapy in Stage III non-small cell lung cancer: Analysis of the National Cancer Data Base.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  23. DE RUYSSCHER D, Lueza B, Le Pechoux C, Johnson DH, et al
    Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  24. FRUH M, Ris HB, Xyrafas A, Peters S, et al
    Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
    Ann Oncol. 2016.
    PubMed     Text format    


  25. GARRIDO P, Palacios J
    Necitumumab in Squamous Non Small Cell Lung Cancer: How to move forward?
    Ann Oncol. 2016.
    PubMed     Text format    


  26. LACOUTURE ME, Keefe DM, Sonis S, Jatoi A, et al
    A Phase II Study (ARCHER 1042) to Evaluate Prophylactic Treatment of Dacomitinib-induced Dermatologic and Gastrointestinal Adverse Events in Advanced Non-Small-Cell Lung Cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  27. KREBBER AM, Jansen F, Witte BI, Cuijpers P, et al
    Stepped Care Targeting Psychological Distress in Head and Neck Cancer and Lung Cancer Patients: a Randomized Controlled Trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  28. RAMALINGAM SS, O'Byrne K, Boyer M, Mok T, et al
    Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ann Oncol. 2016.
    PubMed     Text format    


  29. PATEL JD, Pereira JR, Chen J, Liu J, et al
    Relationship between Efficacy Outcomes and Weight Gain during Treatment of Advanced, Nonsquamous, Non-small Cell Lung Cancer Patients.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  30. PAZ-ARES L, Socinski MA, Shahidi J, Hozak RR, et al
    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients wit
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  31. CHATTERJEE M, Turner DC, Felip E, Lena H, et al
    Systematic evaluation of pembrolizumab dosing in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  32. VAN KRUIJSDIJK RC, Visseren FL, Boni L, Groen HJ, et al
    Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small cell lung cancer: treating the right patients based on individualized treatment effect prediction.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  33. KANAI O, Fujita K, Okamura M, Nakatani K, et al
    Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.
    Ann Oncol. 2016.
    PubMed     Text format    


  34. MORROW CJ, Trapani F, Metcalf RL, Bertolini G, et al
    Tumourigenic Non-Small Cell Lung Cancer Mesenchymal Circulating Tumour Cells - A Clinical Case Study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  35. CHERNY NI, Kloke M, Cervantes A, Pentheroudakis G, et al
    Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.
    Ann Oncol. 2016;27:550-1.
    PubMed     Text format    


    February 2016
  36. BRACARDA S
    More colors to the palette.
    Ann Oncol. 2016;27:363.
    PubMed     Text format    


    January 2016
  37. JAMAL-HANJANI M, Wilson GA, Horswell S, Mitter R, et al
    Detection of Ubiquitous and Heterogeneous Mutations in Cell-Free DNA from Patients with Early-Stage Non-Small-Cell Lung Cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  38. TAKEGAWA N, Hayashi H, Iizuka N, Takahama T, et al
    Transformation of ALK rearrangement-positive adenocarcinoma to small cell lung cancer in association with acquired resistance to alectinib.
    Ann Oncol. 2016.
    PubMed     Text format    


  39. CARTER CA, Rajan A, Keen C, Szabo E, et al
    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced non-small cell lung cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  40. DOWLATI A, Lipka MB, McColl K, Dabir S, et al
    Clinical Correlation of Extensive-Stage Small Cell Lung Cancer Genomics.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  41. TAKEDA M, Sakai K, Okamoto K, Hayashi H, et al
    Genome sequencing for non-small cell lung cancer identifies a basis for nintedanib sensitivity.
    Ann Oncol. 2016.
    PubMed     Text format    


  42. RAMALINGAM SS, O'Byrne K, Boyer M, Mok T, et al
    Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  43. JOHNSON MJ, Currow DC
    How much evidence isn't in evidence-based guidelines?
    Ann Oncol. 2016;27:205.
    PubMed     Text format    


  44. BASSO U, Maruzzo M
    More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis.
    Ann Oncol. 2016;27:202-3.
    PubMed     Text format    


    December 2015
  45. SCHILD SE, Vokes EE
    Pathways to improving combined modality therapy for stage III non-small cell lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  46. TREASURE T, Macbeth F
    The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastases.
    Ann Oncol. 2015.
    PubMed     Text format    


  47. BEAU-FALLER M, Cadranel J
    Reply to the letter to the editor "Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients" by Krawczyk et al.
    Ann Oncol. 2015.
    PubMed     Text format    


  48. SCHULER M, Yang JC, Park K, Kim JH, et al
    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  49. MAZIERES J, Barlesi F, Filleron T, Besse B, et al
    Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EUHER2 cohort.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  50. SWANTON C, Boffetta P, Peston R, Soria JC, et al
    Environmental Emissions, Public Health and Lung Cancer Risk.
    Ann Oncol. 2015.
    PubMed     Text format    


  51. KRAWCZYK P, Reszka K, Ramlau R, Powrozek T, et al
    Prevalence of rare EGFR gene mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients.
    Ann Oncol. 2015.
    PubMed     Text format    


  52. DONNEM T, Kilvaer TK, Andersen S, Richardsen E, et al
    Strategies for clinical implementation of TNM-immunoscore in resected non-small cell lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  53. GOLDMANN T, Kugler C, Reinmuth N, Vollmer E, et al
    PD-L1 copy number gain in Non Small Cell Lung Cancer defines a new subset of patients for anti PD-L1 therapy.
    Ann Oncol. 2015.
    PubMed     Text format    


  54. TAKEUCHI K, Togashi Y, Kamihara Y, Fukuyama T, et al
    Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  55. TAKEDA M, Sakai K, Terashima M, Kaneda H, et al
    Clinical application of amplicon-based next-generation sequencing to therapeutic decision-making in lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  56. MIDDLETON G, Crack LR, Popat S, Swanton C, et al
    The National Lung Matrix Trial: Translating the Biology of Stratification in Advanced Non-Small Cell Lung Cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  57. MICHELS J, Adam J, Goubar A, Obrist F, et al
    Negative prognostic value of high levels of intracellular poly (ADP-ribose) in non-small cell lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  58. VIEIRA AR, Abar L, Vingeliene S, Chan DS, et al
    Fruits, vegetables and lung cancer risk: a systematic review and meta-analysis.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  59. DAVIDSON A, Veillard AS, Tognela A, Chan MM, et al
    A phase 3 randomized trial of adding topical nitroglycerin to first line chemotherapy for advanced non-small-cell lung cancer: The Australasian Lung cancer Trials Group NITRO Trial.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  60. DINGEMANS AC, Groen HJ, Herder GJ, Stigt JA, et al
    A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT 12 (NCT01171170).
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  61. PIETRANTONIO F, Cremolini C
    Authors' Response: how to address the issue of "rare" mutations for improving colorectal cancer patients' care.
    Ann Oncol. 2015.
    PubMed     Text format    


    August 2015
  62. SCAGLIOTTI GV, Di Maio M
    Tivantinib added to Erlotinib in Non-Small Cell Lung Cancer: the primary endpoint was not MET....
    Ann Oncol. 2015.
    PubMed     Text format    


    July 2015
  63. THOMAS A, Giaccone G
    Why has active immunotherapy not worked in lung cancer?
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  64. YOSHIOKA H, Azuma K, Yamamoto N, Takahashi T, et al
    A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV non-squamous non-small-cell lung cancer harboring wild-type epi
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  65. ZHOU C, Wu YL, Chen G, Feng J, et al
    Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    June 2015
  66. ENGELEN MP, Safar AM, Bartter T, Koeman F, et al
    High Anabolic Potential of Essential Amino acid Mixtures in Advanced Non-Small Cell Lung Cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  67. WU YL, Zhou C, Liam CK, Wu G, et al
    First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  68. TOGASHI Y, Mizuuchi H, Kobayashi Y, Hayashi H, et al
    An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer.
    Ann Oncol. 2015.
    PubMed     Text format    


  69. RAMALINGAM S, Goss G, Rosell R, Schmid-Bindert G, et al
    A Randomized Phase 2 Study Of Ganetespib, A Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Second-Line Therapy Of Advanced Non-Small-Cell Lung Cancer (GALAXY-1).
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  70. ILIE M, Hofman P
    Reply to the letter to the editor "ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer" by Uguen et al.
    Ann Oncol. 2015.
    PubMed     Text format    


    March 2015
  71. LANDI L, Cappuzzo F
    Nit-picking around second line in EGFRwt NSCLC: just an academic effort.
    Ann Oncol. 2015;26:448-50.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: